Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00477633
Other study ID # PR-00207
Secondary ID
Status Completed
Phase Phase 3
First received May 22, 2007
Last updated April 15, 2013
Start date June 2007
Est. completion date February 2009

Study information

Verified date April 2013
Source Warner Chilcott
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a non-comparative study. the primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.


Recruitment information / eligibility

Status Completed
Enrollment 1700
Est. completion date February 2009
Est. primary completion date January 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy Women

- Age 18-45

- At risk for pregnancy

- History of regular cycles

Exclusion Criteria:

- Contraindications for use of hormonal contraception

- Conditions which affect the absorption or metabolism of steroid hormones

- BMI>35

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Norethindrone/ethinyl estradiol
1 tablet per day

Locations

Country Name City State
United States Warner Chilcott Investigational Site Amite Louisiana
United States Warner Chilcott Investigational Site Arkansas City Kansas
United States Warner Chilcott Investigational Site Austin Texas
United States Warner Chilcott Investigational Site Austin Texas
United States Warner Chilcott Investigational Site Berlin New Jersey
United States Warner Chilcott Investigational Site Boynton Beach Florida
United States Warner Chilcott Investigational Site Brooksville Florida
United States Warner Chilcott Investigational Site Cary North Carolina
United States Warner Chilcott Investigational Site Castle Rock Colorado
United States Warner Chilcott Investigational Site Champaign Illinois
United States Warner Chilcott Investigational Site Chandler Arizona
United States Warner Chilcott Investigational Site Chaska Minnesota
United States Warner Chilcott Investigational Site Clearwater Florida
United States Warner Chilcott Investigational Site Cleveland Ohio
United States Warner Chilcott Investigational Site Columbia South Carolina
United States Warner Chilcott Investigational Site Dallas Texas
United States Warner Chilcott Investigational Site Decatur Georgia
United States Warner Chilcott Investigational Site Denver Colorado
United States Warner Chilcott Investigational Site Edison New Jersey
United States Warner Chilcott Investigational Site Gainesville Florida
United States Warner Chilcott Investigational Site Houston Texas
United States Warner Chilcott Investigational Site Indianapolis Indiana
United States Warner Chilcott Investigational Site Jacksonville Florida
United States Warner Chilcott Investigational Site Lakewood Colorado
United States Warner Chilcott Investigational Site Lawrenceville New Jersey
United States Warner Chilcott Investigational Site Leesburg Florida
United States Warner Chilcott Investigational Site Lexington Kentucky
United States Warner Chilcott Investigational Site Louisville Kentucky
United States Warner Chilcott Investigational Site Magna Utah
United States Warner Chilcott Investigational Site Marrero Louisiana
United States Warner Chilcott Investigational Site Medford Oregon
United States Warner Chilcott Investigational Site Miami Florida
United States Warner Chilcott Investigational Site Miami Florida
United States Warner Chilcott Investigational Site Moorestown New Jersey
United States Warner Chilcott Investigational Site New Bern North Carolina
United States Warner Chilcott Investigational Site New York New York
United States Warner Chilcott Investigational Site Norfolk Virginia
United States Warner Chilcott Investigational Site Oklahoma City Oklahoma
United States Warner Chilcott Investigational Site Pembroke Pines Florida
United States Warner Chilcott Investigational Site Peoria Illinois
United States Warner Chilcott Investigational Site Philadelphia Pennsylvania
United States Warner Chilcott Investigational Site Phoenix Arizona
United States Warner Chilcott Investigational Site Phoenix Arizona
United States Warner Chilcott Investigational Site Phoenix Arizona
United States Warner Chilcott Investigational Site Pittsburgh Pennsylvania
United States Warner Chilcott Investigational Site Pottstown Pennsylvania
United States Warner Chilcott Investigational Site Raleigh North Carolina
United States Warner Chilcott Investigational Site Richmond Virginia
United States Warner Chilcott Investigational Site Salt Lake City Utah
United States Warner Chilcott Investigational Site Salt Lake City Utah
United States Warner Chilcott Investigational Site San Antonio Texas
United States Warner Chilcott Investigational Site San Diego California
United States Warner Chilcott Investigational Site San Diego California
United States Warner Chilcott Investigational Site St. Petersburg Florida
United States Warner Chilcott Investigational Site Tempe Arizona
United States Warner Chilcott Investigational Site Tucson Arizona
United States Warner Chilcott Investigational Site Virginia Beach Virginia
United States Warner Chilcott Investigational Site Vista California
United States Warner Chilcott Investigational Site West Palm Beach Florida
United States Warner Chilcott Investigational Site West Palm Beach Florida
United States Warner Chilcott Investigational Site West Valley City Utah
United States Warner Chilcott Investigational Site Wichita Kansas
United States Warner Chilcott Investigational Site Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Warner Chilcott

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pearl Index, 18-35 Years, MITT Population Pregnancy rate in women 18-35 years old, Pearl Index - number of pregnancies per 100 women-years of treatment 13 cycles (28 days each), approximately 364 days No
Secondary Mean Number of Days of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population 12 cycles (28 days each), approximately 336 days No
Secondary Mean Median Duration (Days) of Intracyclic Bleeding & Spotting, Cycles 2-13, MITT Population Each IB episode has a unique duration, with 0, 1, 2, 3 or more episodes per cycle. To obtain "mean median duration" of episodes during a cycle, take the median duration of all episodes in each cycle. If there are no episodes in the cycle, then median duration is undefined/missing for that cycle. 1 episode - median duration = duration of that episode, 2 episodes - median duration = average of 2 durations, more than 2 episodes, calculated in usual way for median of an ordered set of numbers. Once median determined for each cycle/subject, the mean & SD of those quantities calculated. 12 cycles (28 days each), approximately 336 days No
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A